The Financial Times has published its 7th annual ranking of the 1000 fastest-growing companies in Europe. Dante Genomic ranks among the top 25, registering a 250.5% CAGR in revenues between 2018 and 2021.
“Growth comes from every function, from every employee, and especially from delivering applications that impact human lives”
said Andrea Riposati, co-founder and CEO of Dante Genomics.
Dante Genomics received the ISO 13485 for medical devices for its Extensa interpretation software in 2020, renewing it in 2021 and again in 2022. The new ISO 15189 is a testament to the Company’s continued investment in quality.
Dante Genomics developed a hybrid approach of local sequencing laboratories in strategic locations with the addition of partnership labs in several other countries to deliver whole genome sequencing globally at scale in more than 97 countries.
The Financial Times ranking, developed with @Statista, analysed thousands of European companies, to select the 1,000 European companies with the highest compound annual percentage growth rates (CAGRs) in revenues in the last 2 years.
About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes, prevention, enhanced diagnostics and personalized medicine. The Company’s assets include one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.
